Assessment of the impact of weekly versus monthly erythropoiesis stimulating protein therapy on patients with CKD and their families.
This cross-sectional study measured patient and family member reported treatment and economic burden associated with monthly versus weekly erythropoiesis stimulating protein therapies for anemia in patients with CKD who were not yet on dialysis. The results indicated that compared to a weekly regimen, a monthly regimen saved patients 7 hours and family members 19 hours per month for routine anemia management. The monthly regimen substantially reduced the reported economic and treatment burdens of patient and their family members.
Globe
Denise
D
Global Health Economics & Outcomes Research, Amgen Inc., Thousand Oaks, CA, USA. dglobe@amgen.com
Glidden
Deborah
D
Hertel
Joachim
J
Thomas
Joele
J
Ackerman
Michele
M
Chidolue
Felicia
F
Blanco
Bianca
B
Borden
Annette
A
Goss
Thomas F
TF
Xu
Xiao
X
Kewalramani
Reshma
R
D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004334:Drug Administration Schedule; D004920:Erythropoiesis; D004921:Erythropoietin / Q000008:administration & dosage*; D005190:Family / Q000523:psychology*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires
D004921:Erythropoietin